Epizyme joins the queue of biotechs now handing out pink slips, conserving cash

You can add Epizyme to the roster of biotechs reorganizing and downsizing — in staff and R&D projects — in the face of a brutal bear market attack.

The biotech put out word today that it has brought out the ax to chop off 12% of its staff, without specifying the numbers. That should be good for approximately $3 million in cost reductions.